⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 1, 2026ESMO rare cancers.Open Access

166P Early progression severely limits access to second-line therapy in recurrent/metastatic complex karyotype soft tissue sarcomas (CKSTS)

S.E. Ruffini Egea N. Pascual de La Fuente P. Trincado Cobos S.E. Campos Ramirez F. Mocha Campillo L.G. Caballero P. Morillas Martínez S. Barriendos Sanz P.G. Mugarza G.M. Guevara Maria L. Cepero J. Martinez Trufero

View Full Paper

Ask AI

Bookmark

Share

Implication

This retrospective analysis finds that early disease progression limits effective second-line therapy access in recurrent metastatic soft tissue sarcomas, indicating the need for timely...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Egea et al. (2026) studied this question.

synapsesocial.com/papers/69b257ec96eeacc4fcec70bc https://doi.org/10.1016/j.esmorc.2026.100372

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1165P Trabectedin or gemcitabine-based chemotherapy as second-line therapy for advanced leiomyosarcoma: An IPTW-adjusted analysisHuman Clinical Trial · 2026
2Treatment Patterns and Healthcare Resource Utilization in Pediatric NF1–Associated Symptomatic PN in the United States from 2000 to 2019Cohort Study · 2026
3Plexiform Neurofibromas and Malignant Peripheral Nerve Sheath Tumors in Adults with Neurofibromatosis Type 1: Clinical Insights from a Large CohortCohort Study · 2026
4Outcomes of malignant peripheral nerve sheath tumors in neurofibromatosis type 1 and sporadic patients: A 25-year experience from a sarcoma referral center.Cohort Study · 2026
5A Retrospective Study of Diffuse Plexiform Neurofibroma With Surgical Intervention in Neurofibromatosis 12025 · 2 citations